The global pseudomonas aeruginosa pneumonia drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in June 2019, Merck & Co has received the approval of the US Food and Drug Administration (FDA) for the use of Zerbaxa. The Zerbaxa is used to treat adult patients ( 18 years and older) with hospital-acquired bacterial infection pneumonia and ventilator-associated pneumonia which is caused by the susceptible gram-negative microorganisms. The company further stated that efficacy was assessed based on all-cause mortality at day 28 and significant signs of improvement occurred after 7 to 14 days at the end of the treatment.
Browse the full report description “Global Pseudomonas Aeruginosa Pneumonia Drug Market Size, Share & Trends Report by Type (Aerucin, EV-035, MEDI-3902, and Others) and by Application (Hospital, Clinic and Others) Forecast (2022-2028)“at https://www.omrglobal.com/industry-reports/pseudomonas-aeruginosa-pneumonia-drug-market
Moreover, in 2019, Teva Pharmaceuticals has launched a Tobramycin inhalation solution. This solution is packaged in plastic containers called ampules. The medicine is used to treat lung infections in patients with cystic fibrosis. Furthermore, in June 2020, Merck & Co received US Food and Drug Administration (FDA) approval for the use of Recarbrio. Recarbrio is used to treat adult patients ( 18years and older) with hospital-acquired bacterial infection pneumonia and ventilator-associated pneumonia. Moreover, recarbrio was previously approved by FDA to treat patients with urinary tract infections who possess no alternative treatments. According to FDA, the safety and efficacy were evaluated in clinical trials of 535 hospitalized adults with VABP. Thus, the application was designated as Qualified Infectious Disease Program (QIDP) by the FDA.
Market Coverage
Segment Covered-
Regions Covered-
Competitive Landscape- Aridis Pharmaceuticals LLC, Johnson & Johnson Services Inc., Medlmmune LLC (Astrazeneca), Pfizer Inc., and more among others.
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Pseudomonas Aeruginosa Pneumonia Drug Market Report Segment
By Type
By Application
Global Pseudomonas Aeruginosa Pneumonia Drug Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World